Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
In the latest session, NewAmsterdam Pharma Company NV (NASDAQ: NAMS) closed at $25.4 up 1.32% from its previous closing price of $25.07. In other words, the price has increased by $1.32 from its previous closing price. On the day, 0.82 million shares were traded. NAMS stock price reached its highest trading level at $25.84 during the session, while it also had its lowest trading level at $24.715.
Ratios:
For a deeper understanding of NewAmsterdam Pharma Company NV’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 21.08 and its Current Ratio is at 21.08. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on July 17, 2025, initiated with a Neutral rating and assigned the stock a target price of $27.
On June 17, 2025, Citigroup started tracking the stock assigning a Buy rating and target price of $42.
On June 10, 2025, Stifel started tracking the stock assigning a Buy rating and target price of $44.Stifel initiated its Buy rating on June 10, 2025, with a $44 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 11 ’25 when Topper James N bought 471 shares for $23.98 per share. The transaction valued at 11,294 led to the insider holds 3,026,604 shares of the business.
Kling Douglas F sold 51,043 shares of NAMS for $1,077,007 on Jul 16 ’25. The Chief Operating Officer now owns 44,000 shares after completing the transaction at $21.10 per share. On Jul 15 ’25, another insider, Kling Douglas F, who serves as the Chief Operating Officer of the company, sold 47,569 shares for $21.44 each. As a result, the insider received 1,019,648 and left with 44,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NAMS now has a Market Capitalization of 2860751104 and an Enterprise Value of 2121928832. For the stock, the TTM Price-to-Sale (P/S) ratio is 44.69 while its Price-to-Book (P/B) ratio in mrq is 3.67. Its current Enterprise Value per Revenue stands at 33.152 whereas that against EBITDA is -12.293.
Stock Price History:
The Beta on a monthly basis for NAMS is -0.01, which has changed by 0.56500304 over the last 52 weeks, in comparison to a change of 0.15222645 over the same period for the S&P500. Over the past 52 weeks, NAMS has reached a high of $27.29, while it has fallen to a 52-week low of $14.06. The 50-Day Moving Average of the stock is 18.41%, while the 200-Day Moving Average is calculated to be 20.41%.
Shares Statistics:
For the past three months, NAMS has traded an average of 856.67K shares per day and 921530 over the past ten days. A total of 112.51M shares are outstanding, with a floating share count of 62.46M. Insiders hold about 43.62% of the company’s shares, while institutions hold 61.57% stake in the company. Shares short for NAMS as of 1753920000 were 7179587 with a Short Ratio of 8.38, compared to 1751241600 on 6875637. Therefore, it implies a Short% of Shares Outstanding of 7179587 and a Short% of Float of 7.6.
Earnings Estimates
The dynamic stock of NewAmsterdam Pharma Company NV (NAMS) is currently being evaluated by a team of 11.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is -$0.38, with high estimates of -$0.26 and low estimates of -$0.49.
Analysts are recommending an EPS of between -$0.94 and -$1.45 for the fiscal current year, implying an average EPS of -$1.21. EPS for the following year is -$1.78, with 9.0 analysts recommending between -$1.32 and -$2.52.
Revenue Estimates
A total of 12 analysts have provided revenue estimates for NAMS’s current fiscal year. The highest revenue estimate was $46.21M, while the lowest revenue estimate was $18.99M, resulting in an average revenue estimate of $27.17M. In the same quarter a year ago, actual revenue was $43.39M
